RxDoctor Payments DataLook up a doctor →

Zara Bogenschutz, PA

Physician Assistant · Indianapolis, INNPI 1639691199

Payments from drug & device makers

$12,318in general payments, 2019–2025

Across 474 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$4K
  • AbbVie$2K
  • Novartis$1K
  • Biogen$557
  • UCB, Inc.$342
  • Sanofi$263
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$12,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,318 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$7,054
Medicare patients
57
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$139,065
Aimovig AutoinjectorErenumab-Aooe79$65,623
QuliptaAtogepant45$59,927
AptiomEslicarbazepine Acetate15$42,227
Nurtec OdtRimegepant Sulfate29$41,362
UbrelvyUbrogepant30$28,836
BriviactBrivaracetam15$22,547
Emgality PenGalcanezumab-Gnlm23$18,937
NeuproRotigotine12$14,499
Lamotrigine ErLamotrigine52$9,523
Levetiracetam125$6,412
Modafinil58$6,391
Lacosamide28$5,828
Gabapentin223$3,743
Carbamazepine28$3,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$194$139,06516 claims
AbbVieQulipta, Ubrelvy$2,430$88,76475 claims
Sunovion Pharmaceuticals Inc.Aptiom$23$42,22715 claims
PfizerNurtec Odt$68$41,36229 claims
UCB, Inc.Briviact, Neupro$342$37,04627 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$38$2,02911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →